Speculations on the clinical significance of asymptomatic viral infections

Clinical Microbiology and Infection

Volumn 22, Issue 7, 2016, Pages 585-588

  Gentile, G ^a   Micozzi, A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Asymptomatic viral infections; Chronic infections; Herpesviruses; Microbiome; Virome

Indexed keywords

ASYMPTOMATIC INFECTION; ASYMPTOMATIC VIRAL INFECTION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; INFECTION; KAPOSI SARCOMA; LYMPHOMA; MALARIA; MALARIA FALCIPARUM; MIXED INFECTION; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS CELL INTERACTION; VIRUS INFECTION; ASYMPTOMATIC INFECTIONS; CAUSALITY; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MICROFLORA; PROCEDURES; STANDARDS; VIROLOGY;

ASYMPTOMATIC INFECTIONS; CAUSALITY; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HUMANS; MICROBIOLOGICAL TECHNIQUES; MICROBIOLOGY; MICROBIOTA;

EID: 84979730154     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.07.016     Document Type: Review

References (62)

1. [1] Virgin, H.W., Wherry, E.J., Ahmed, R., Redefining chronic viral infection. Cell 138 (2009), 30–50.
2. [2] Wylie, K.M., Mihindukulasuriya, K.A., Zhou, Y., Sodergren, E., Storch, G.A., Weinstock, G.M., Metagenomic analysis of double-stranded DNA viruses in healthy adults. BMC Biol, 10(12), 2014, 71.
3. [3] Bernardin, F., Operskalski, E., Busch, M., Delwart, E., Transfusion transmission of highly prevalent commensal human viruses. Transfusion 50 (2010), 2474–2483.
4. [4] Suk-Fong Lok, A., Hepatitis B: 50 years after the discovery of Australia antigen. J Viral Hepat 23 (2016), 5–14.
5. [5] Cho, I., Blaser, M.J., The human microbiome at the interface of health and disease. Nat Rev Genet 13 (2012), 260–270.
6. [6] Virgin, H.W., The virome in mammalian physiology and disease. Cell 157 (2014), 142–150.
7. [7] Hooper, L.V., Littman, D.R., Macpherson, A.J., Interaction between the microbiota and the immune system. Science 336 (2012), 1268–1273.
8. [8] Cadwell, K., The virome in host health and disease. Immunity 42 (2015), 805–813.
9. [9] Thakker, S., Verma, S.C., Co-infections and pathogenesis of KSHV-associated malignancies. Front Microbiol, 7, 2016, 151.
10. [10] Rickinson, A.B., Co-infections, inflammation and oncogenesis: future directions for EBV research. Semin Cancer Biol 26 (2014), 99–115.
11. [11] Reese, T.A., Co-infections: another variable in the herpesvirus latency-reactivation dynamic. J Virol 90 (2016), 5534–5537.
12. [12] Byrd, A.L., Segre, J.A., Adapting Koch's postulates. Science 351 (2016), 224–226.
13. [13] Koch, R., Zer Untersuchung van pathogen organismen: Mittheil. Kais. Gesundheitsamte 1 (1881), 1–48.
14. [14] Henle, J., Rosen, G., Jacob Henle on miasmata and contagia. 1938, The Johns Hopkins Press, Baltimore.
15. [15] Evans, A.S., Causation and disease: a chronological journey. Am J Epidemiol 108 (1978), 249–258.
16. [16] Pierangeli, A., Antonelli, G., Gentile, G., Immunodeficiency-associated viral oncogenesis. Clin Microbiol Infect 21 (2015), 975–983.
17. [17] Hill, A.B., Environment and disease: association of causation. Proc R Soc Med 58 (1965), 295–300.
18. [18] Moore, P.S., Chang, Y., The conundrum of causality in tumor virology: the cases of KSHV and MCV. Semin Cancer Biol 26 (2014), 4–12.
19. [19] White, M.K., Pagano, J., Khalili, K., Viruses and human cancers: a long road of discovery of molecular paradigms. Clin Microbiol Rev 27 (2014), 463–481.
20. [20] Virgin, H.W., Todd, J.A., Metagenomics and personalized medicine. Cell 147 (2011), 44–56.
21. [21] Cox, M.J., Cookson, W.O., Moffatt, M.F., Sequencing the human microbiome in health and disease. Hum Mol Genet 22 (2013), R88–R94.
22. [22] Mulcahy-O'Grady, H., Workentine, M.L., The challenge and potential of metagenomics in the clinic. Front Immunol, 7, 2016, 29.
23. [23] Wylie, K.M., Weinstock, G.M., Storch, G.A., Virome genomics: a tool for defining the human virome. Curr Opin Microbiol 16 (2013), 479–484.
24. [24] Bikel, S., Valdez-Lara, A., Cornejo-Granados, F., Rico, K., Canizales-Quinteros, S., Soberón, X., et al. Combining metagenomics, metatranscriptomics and viromics to explore novel microbial interactions: towards a systems-level understanding of human microbiome. Comput Struct Biotechnol J 13 (2015), 390–401.
25. [25] Gentile, G., Mele, A., Ragona, G., Faggioni, A., Zompetta, C., Tosti, M.E., et al. Human herpes virus-6 seroprevalence and leukaemias: a case-control study. GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto. Br J Cancer 80 (1999), 1103–1106.
26. [26] Razonable, R.R., Human herpesviruses 6,7 and 8 in solid organ transplant recipients. Am J Transplant 13:S3 (2013), 67–78.
27. [27] Agut, H., Deciphering the clinical impact of acute human herpesvirus 6 (HHV-6) infections. J Clin Virol 52 (2011), 164–171.
28. [28] Amon, W., Farrell, P.J., Reactivation of Epstein–Barr virus from latency. Rev Med Virol 15 (2005), 149–156.
29. [29] Gorres, K.L., Daigle, D., Mohanram, S., Miller, G., Activation and repression of Epstein–Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids. J Virol 88 (2014), 8028–8044.
30. [30] Doolittle, J.M., Webster-Cyriaque, J., Polymicrobial infection and bacterium-mediated epigenetic modification of DNA tumor viruses contribute to pathogenesis. Mbio, 5, 2014, e01015-14.
31. [31] Morris, T.L., Arnold, R.R., Webster-Cyriaque, J., Signaling cascades triggered by bacterial metabolic end products during reactivation of Kaposi's sarcoma-associated herpesvirus. J Virol 81 (2007), 6032–6042.
32. [32] Imai, K., Inoue, H., Tamura, M., Cueno, M.E., Inoue, H., Takeichi, O., et al. The periodontal pathogen Porphyromonas gingivalis induces the Epstein–Barr virus lytic switch transactivator ZEBRA by histone modification. Biochimie 94 (2012), 839–846.
33. [33] Gentile, G., Antonelli, G., Interplay between B herpesviruses and fungal infections in transplant patients: from the bench to bedside. Future Virol 10 (2015), 399–414.
34. [34] Gentile, G., Post-transplant HHV-6 diseases. Herpes 7 (2000), 24–27.
35. [35] Gentile, G., Capobianchi, A., Ferraironi, M., Greco, E., Martino, P., Relationship of serum human herpesvirus 6 DNA with cytomegalovirus pp65 antigenemia in allogeneic bone marrow transplant recipients. Transplantation 77 (2004), 1907–1908.
36. [36] Barton, E.S., White, D.W., Cathelyn, J.S., Brett-McClellan, K.A., Engle, M., Diamond, M.S., et al. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 447 (2007), 326–329.
37. [37] Raffegerst, S., Steer, B., Hohloch, M., Adler, H., Prevention of tumor formation by latent gammaherpesvirus infection. PLoSOne, 10, 2015, e0145678.
38. [38] Furman, D., Jojic, V., Sharma, S., Shen-Orr, S.S., Angel, C.J., Onengut-Gumuscu, S., et al. Cytomegalovirus infection enhances the immune response to influenza. Sci Transl Med, 7, 2015, 281ra43.
39. [39] Onyeagocha, C., Hossain, M.S., Kumar, A., Jones, R.M., Roback, J., Gewirtz, A.T., Latent cytomegalovirus infection exacerbates experimental colitis. Am J Pathol 175 (2009), 2034–2042.
40. [40] Balfour, H.H., Dunmire, S.K., Hogquist, K.A., Infectious mononucleosis. Clin Transl Immunol, 4, 2015, e33.
41. [41] Piriou, E., Asito, A.S., Sumba, P.O., Fiore, N., Middeldorp, J.M., Moormann, A.M., et al. Early age at time of primary Epstein–Barr virus infection results in poorly controlled viral infection in infants from Western Kenya: clues to the etiology of endemic Burkitt lymphoma. J Infect Dis 205 (2012), 906–913.
42. [42] Rainey, J.J., Mwanda, W.O., Wairiumu, P., Moormann, A.M., Wilson, M.L., Rochford, R., Spatial distribution of Burkitt's lymphoma in Kenya and association with malaria risk. Trop Med Int Health 12 (2007), 936–943.
43. [43] Matar, C.G., Jacobs, N.T., Speck, S.H., Lamb, T.J., Moormann, A., Does EBV alter the pathogenesis of malaria?. Parasite Immunol 37 (2015), 433–445.
44. [44] Schmidt, C.Q., Kennedy, A.T., Tham, W.H., More than just immune evasion: Hijacking complement by Plasmodium falciparum. Mol Immunol 67 (2015), 71–84.
45. [45] de-Thé, G., Geser, A., Day, N.E., Tukei, P.M., Williams, E.H., Beri, D.P., et al. Epidemiological evidence for causal relationship between Epstein–Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature 274 (1978), 756–761.
46. [46] Reynaldi, A., Schlub, T.E., Chelimo, K., Sumba, P.O., Piriou, E., Ogolla, S., et al. Impact of Plasmodium falciparum coinfection on longitudinal Epstein–Barr virus kinetics in Kenyan children. J Infect Dis 213 (2016), 985–991.
47. [47] Janz, S., Potter, M., Rabkin, C.S., Lymphoma- and leukemia-associated chromosomal translocations in healthy individuals. Genes Chromosomes Cancer 36 (2003), 211–223.
48. [48] Torgbor, C., Awuah, P., Deitsch, K., Kalantari, P., Duca, K.A., Thorley-Lawson, D.A., A multifactorial role for P. falciparum malaria in endemic Burkitt's lymphoma pathogenesis. PLoS Pathog, 10, 2014, e1004170.
49. [49] Robbiani, D.F., Deroubaix, S., Feldhahn, N., Oliveira, T.Y., Callen, E., Wang, Q., et al. Plasmodium infection promotes genomic instability and AID-dependent B cell lymphoma. Cell 162 (2015), 727–737.
50. [50] Schulz, T.F., Cesarman, E., Kaposi sarcoma-associated herpesvirus: mechanisms of oncogenesis. Curr Opin Virol 14 (2015), 116–128.
51. [51] Dittmer, D.P., Damania, B., Kaposi sarcoma associated herpesvirus pathogenesis (KSHV)- an update. Curr Opin Virol 3 (2013), 238–244.
52. [52] Reese, T.A., Wakeman, B.S., Choi, H.S., Hufford, M.M., Huang, S.C., Zhang, X., et al. Helminth infection reactivates latent γ-herpesvirus via cytokine competition at a viral promoter. Science 345 (2014), 573–577.
53. [53] Osborne, L.C., Monticelli, L.A., Nice, T.J., Sutherland, T.E., Siracusa, M.C., Hepworth, M.R., et al. Coinfection. Virus–helminth coinfection reveals a microbiota-independent mechanism of immunomodulation. Science 345 (2014), 578–582.
54. [54] Hotez, P.J., Molyneux, D.H., Fenwick, A., Kumaresan, J., Sachs, S.E., Sachs, J.D., et al. Control of neglected tropical diseases. N Engl J Med 357 (2007), 1018–1027.
55. [55] Wakeham, K., Webb, E.L., Sebina, I., Muhangi, L., Miley, W., Johnson, W.T., et al. Parasite infection is associated with Kaposi's sarcoma associated herpesvirus (KSHV) in Ugandan women. Infect Agent Cancer, 6, 2011, 15.
56. [56] Wakeham, K., Webb, E.L., Sebina, I., Nalwoga, A., Muhangi, L., Miley, W.J., et al. Risk factors for seropositivity to Kaposi sarcoma-associated herpesvirus among children in Uganda. J Acquir Immune Defic Syndr 63 (2013), 228–233.
57. [57] Nascimento, M.C., Malaria may influence the transmission of Kaposi sarcoma associated herpesvirus in endemic areas. J Acquir Immune Defic Syndr 67 (2014), e41–e43.
58. [58] Nalwoga, A., Cose, S., Wakeham, K., Miley, W., Ndibazza, J., Drakeley, C., et al. Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda. Trop Med Int Health 20 (2015), 665–672.
59. [59] Stolka, K., Ndom, P., Hemingway-Foday, J., Iriondo-Perez, J., Miley, W., Labo, N., et al. Risk factors for Kaposi's sarcoma among HIV-positive individuals in a case control study in Cameroon. Cancer Epidemiol 38 (2014), 137–143.
60. [60] Casadevall, A., Pirofski, L., What is a host? Incorporating the microbiota into the damage-response framework. Infect Immun 83 (2015), 2–7.
61. [61] Pfeiffer, J.K., Virgin, H.W., Viral immunity. Transkingdom control of viral infection and immunity in the mammalian intestine. Science, 351(6270), 2016.
62. [62] De Vlaminck, I., Khush, K.K., Strehl, C., Kohli, B., Luikart, H., Neff, N.F., et al. Temporal response of the human virome to immunosuppression and antiviral therapy. Cell 155 (2013), 1178–1187.